Figure 1.

Change in glycated hemoglobin (%) from baseline to each visit between baseline and week 24 with a mixed model with repeated-measures analysis (A) and change in least squares (LS) mean at week 24 (evaluable analysis set) (B). Adjusted LS means at each visit were modeled with use of a mixed model with repeated measures including treatment group, region, visit, treatment group–by–visit interaction, baseline glycated hemoglobin level (continuous), and baseline glycated hemoglobin–by–visit interaction as fixed effects, with an unstructured covariance matrix. Baseline was defined as the last nonmissing assessment (scheduled or unscheduled) on or prior to the first dose of the randomized study medication. Data collected after the initiation of rescue medication or after premature discontinuation of the study medication were excluded.